Bridgebio Oncology Therapeutics, Inc. (BBOT)
2.17
-0.13
(-5.65%)
USD |
NASDAQ |
Nov 05, 16:00
2.18
+0.01
(+0.46%)
After-Hours: 20:00
Bridgebio Oncology Therapeutics SG&A Expense (TTM) : 36.80M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 36.80M |
| March 31, 2026 | 26.96M |
| December 31, 2025 | 23.01M |
| September 30, 2025 | 17.89M |
| June 30, 2025 | 3.908M |
| March 31, 2025 | 2.786M |
| Date | Value |
|---|---|
| December 31, 2024 | 0.3653M |
| September 30, 2024 | 0.1469M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Korsana Biosciences, Inc. | 7.127M |
| IRulya Therapeutics, Inc. | 27.81M |
| PepGen Inc. | 23.44M |
| Q32 Bio, Inc. | 13.91M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |